Motexafin gadolinium. Apoptosis inducer radiation enhancer thioredoxin reductase inhibitor ribonucleotide reductase inhibitor

Drugs of the Future

Volumn 32, Issue 7, 2007, Pages 601-606

  Ortiz De Montellano, P R ^a   Evans, J P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ENZYME INHIBITOR; GADOLINIUM TEXAPHYRIN; IBRITUMOMAB TIUXETAN; PEMETREXED; RADIOSENSITIZING AGENT; RIBONUCLEOTIDE REDUCTASE; RITUXIMAB; TEMOZOLOMIDE; THIOREDOXIN REDUCTASE; YTTRIUM 90;

APOPTOSIS; ARTICLE; BRAIN EDEMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL SURVIVAL; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME INHIBITION; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION REDUCTION REACTION; RADIATION ATTENUATION; SKIN DISCOLORATION; UNSPECIFIED SIDE EFFECT;

EID: 34548681863     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.07.1113618     Document Type: Article

References (32)

1. Sessler, J.L., Miller, R.A., Harriman, A.M. (Pharmacyclics, Inc.; Univ. Texas). Radiation sensitization using texaphyrins. US 5622946.
2. Sessler, J.L., Ross, K.L., Wright, M. et al. (Univ. Texas; Pharmacyclics, Inc.). Texaphyrin metal complex mediated ester hydrolysis. WO 9429316.
3. Sessler, J.L., Mody, T.D., Hemmi, G.W., Lynch, V. Synthesis and structural characterization of lanthanide(III) texaphyrins. Inorg Chem 1993, 32(14): 3175-87.
4. Young, S.W., Qing, F., Harriman, A. et al. Gadolinium(III) texaphyrin: A tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci USA 1996, 93(13): 6610-5.
5. Magda, D., Wang, Z., Gerasimchuk, N., Wei, W., Anzenbacher, P., Sessler, J.L. Synthesis of texaphyrin conjugates. Pure Appl Chem 2004, 76(2): 365-74.
6. Sessler, J.L., Tvermoes, N.A., Guldi, D.M., Mody, T.D., Allen, W.E. One-electron reduction and oxidation studies of the radiation sensitizer gadolinium(III) texaphyrin (PCI-0120) and other water soluble metallotexaphyrins. J Phys Chem A 1999, 103(7): 787-94.
7. Magda, D., Lepp, C., Gerasimchuk, N. et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 2001, 51(4): 1025-36.
8. Evens, A.M., Lecane, P., Magda, D. et al. Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood 2005, 105(3): 1265-73.
9. Magda, D., Lecane, P., Miller, R.A. et al. Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res 2005, 65(9): 3837-45.
10. Hashemy, S.I., Ungerstedt, J.S., Zahedi Avval, F., Holmgren, A. Motexafin gadolinium, a tumor selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 2006, 281(16): 10691-7.
11. Evans, J.P., Xu, F., Sirisawad, M., Miller, R., Naumovski, L., Ortiz de Montellano, P.R. Motexafin gadolinium-induced cell death correlates with heme oxygenase-1 expression and inhibition of P450 reductase-dependent activities. Mol Pharmacol 2007, 71(1): 193-200.
12. Viala, J., Vanel, D., Meingan, P., Lartigau, E., Carde, P., Renschler, M. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases. Radiology 1999, 212(3): 755-9.
13. Woodburn, K.W. Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy. J Pharmacol Exp Ther 2001, 297(3): 888-94.
14. Boswell, G.W., Miles, D.R., Thiemann, P.A., Mesfin, M. Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin) in CD1 mice following intravenous and intraperitoneal injection. Invest New Drugs 2006, 24(4): 281-9.
15. Miller, R.A., Woodburn, K., Fan, Q., Renschler, M.F., Sessler, J.L., Koutcher, J.A. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys 1999, 45(4): 981-9.
16. Miles, D.R., Mesfin, M., Mody, T.D. et al. Validation and use of three complementary analytical methods (LC-FLS, LC-MS/MS and ICP-MS) to evaluate the pharmacokinetics, biodistribution and stability of motexafin gadolinium in plasma and tissues. Anal Bioanal Chem 2006, 385(2): 345-56.
17. Ramanathan, R.K., Fakih, M., Mani, S. et al. Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. Cancer Chemother Pharmacol 2006, 57(4): 465-74.
18. Mani, C., Upadhyay, S., Lacy, S., Boswell, G.W., Miles, D.R. Reductase-mediated metabolism of motexafin gadolinium (Xcytrin) in rat and human liver subcellular fractions and purified enzyme preparations. J Pharm Sci 2005, 94(3): 559-70.
19. Magda, D., Miller, R.A. Motexafin gadolinium: A novel redox active drug for cancer therapy. Semin Cancer Biol 2006, 16(6): 466-76.
20. Rosenthal, D.I., Nurenberg, P., Becerra, C.R. et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999, 5(4): 739-45.
21. Mehta, M.P., Rodrigus, P., Terhaard, C.H. et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003, 21(13): 2529-36.
22. Carde, P., Timmerman, R., Mehta, M.P. et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2001, 19(7): 2074-83.
23. Meyers, C.A., Smith, J.A., Bezjak, A. et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial. J Clin Oncol 2004, 22(1): 157-65.
24. Mehta, M.P., Gervais, R., Chabot, P. et al. Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006] 2006, 24(18, Suppl): Abst 7014.
25. Shapiro, W.R., Mehta, M.P., Langer, C. et al. Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase III trials. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 2010.
26. Motexafin gadolinium, temozolomide, and radiation therapy in treating patients with newly diagnosed glioblastoma multiforme (NCT00305864). ClinicalTrials.gov Web site, June 25, 2007.
27. Motexafin gadolinium and radiation therapy in treating young patients with pontine glioma (NCT00387790). ClinicalTrials.gov Web site, June 25, 2007.
28. Trial of motexafin gadolinium and pemetrexed (Alimta®) for second line treatment in patients with non-small cell lung cancer (NCT00365183). ClinicalTrials.gov Web site, June 25, 2007.
29. Motexafin gadolinium, rituximab, and yttrium Y 90 ibritumomab tiuxetan in treating patients with stage II, stage III, or stage IV relapsed or refractory non-Hodgkin's lymphoma (NCT00089284). ClinicalTrials.gov Web site, June 25, 2007.
30. Study of motexafin gadolinium (MGd) for second line treatment of non-small-cell lung cancer (NCT00129844). ClinicalTrials.gov Web site, June 25, 2007.
31. Study of the effect on non-small cell lung cancer of the investigational drug motexafin gadolinium when used in combination with docetaxel (Taxotere) (NCT00373204). ClinicalTrials.gov Web site, June 25, 2007.
32. FDA accepts Xyctrin NDA for filing. DailyDrugNews.com, April 25, 2007.